You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Adherence to Antidepressant Combinations and Monotherapy for Major Depressive Disorder: A CO-MED Report of Measurement-Based Care

WARDEN, DIANE PhD, MBA; TRIVEDI, MADHUKAR H. MD; CARMODY, THOMAS PhD; TOUPS, MARISA MD; ZISOOK, SIDNEY MD; LESSER, IRA MD; MYERS, ALYSON MD; KURIAN, KOLETTE RING BENJI MD; MORRIS, DAVID PhD; JOHN RUSH, A. MD

Journal of Psychiatric Practice:
doi: 10.1097/01.pra.0000445246.46424.fe
Articles
Abstract

Background. Non-adherence to antidepressant treatment is not routinely measured in practical clinical trials. It has not been related to outcomes in a large sample of adults with chronic and/or recurrent major depressive disorder (MDD) or any sample treated with antidepressant combinations. Methods. Adult outpatients with chronic and/or recurrent MDD were randomized to 12 weeks of treatment with bupropion-SR plus escitalopram, venlafaxine–XR plus mirtazapine, or escitalopram plus placebo. We compared non-adherence (the frequency with which daily medications were not taken) and specifically the frequency of temporarily stopping and/or skipping medication, or reducing or increasing the dose across treatments in 567 participants using a self-report questionnaire collected at each visit. We tested the association between non-adherence, and both treatment type and outcomes. Results. A non-adherence rate under 10% was reported by 77.9%, 70.9%, and 71.6% of participants during weeks 1–4, 5–12, and 1–12, respectively. Antidepressant combinations were associated with a higher non-adherence rate than monotherapy during weeks 1–4 and 1–12. During weeks 1–4, 24.1% stopped/skipped doses and 6.1% reduced the dose. During weeks 5–12, 34.7% stopped/skipped doses and 9.4% reduced the dose. Across 12 weeks, 43.2% stopped/skipped doses, and 12.9% reduced the dose. Stopping/skipping doses during all time frames and dose decreases during weeks 1–12 occurred most frequently with combination treatments. Non-adherence was unrelated to symptom remission, response, or symptom change. Conclusions. With closely monitored treatment, non-adherence is low and unrelated to depressive symptom outcome. Nonadherence is highest with antidepressant combinations. Specific non-adherent events are most often sporadic. (Journal of Psychiatric Practice 2014;20:118–132)

Author Information

WARDEN, TRIVEDI, CARMODY, TOUPS, MYERS, RING, KURIAN, and MORRIS: University of Texas Southwestern Medical Center at Dallas; ZISOOK: University of California San Diego and San Diego VA Healthcare System; LESSER: Harbor- UCLA Medical Center, Torrance, CA; RUSH: Duke-National University of Singapore Graduate Medical School, Singapore

Clinical Trials Registry: ClinicalTrials.gov, NCT00590863

For disclaimers and acknowledgments see page 129.

Please send correspondence to: Diane Warden, PhD, MBA, Department of Psychiatry, The University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, TX 75390-9119. dianewwarden@gmail.com

© 2014 by Lippincott Williams & Wilkins, Inc.